Potential utility of antineoplaston A-10 levels in breast cancer

Cancer Letters

Volumn 155, Issue 1, 2000, Pages 67-70

  Badria, Farid ^a   Mabed, Mohamed ^b   Khafagy, Wael ^b   Abou Zeid, Liala ^a  

^a Mansoura University 35516   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Antineoplaston A 10; Breast cancer; Screening

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; AMINO ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; BENZENEACETAMIDES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; FEMALE; HUMANS; MIDDLE AGED; PEPTIDES; PIPERIDONES; RISK;

EID: 0034601182     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00408-0     Document Type: Article

References (29)

1. Miwa I., Erdos E.G., Seki T. Presence of three peptides in urinary kinin (substance Z) preparations. Life Sci. 7:1968;1339-1343.
2. Wollheim E., Nast H.P. A humoral factor in the genesis of essential hypertension. Klin. Wochenschr. 49:1971;426-433.
3. Bruzynski S.R., Georgiades J. Effects of urinary peptides on DNA RNA and protein synthesis in normal and neoplastic cells. Fed. Proc. 32:1973;677.
4. Bruzynski S.R., Loo T.L., Ho D.H., Rao P.N., Georgiades J., Kratzenstein H. Biologically active peptides in human urine. Physiol. Chem. Phys. 8:1976;13-22.
5. Bruzynski S.R., Stolzmann Z., Szopa B., Stolzmann E., Kaltenberg O.P. Antineoplaston A in cancer therapy. Physiol. Chem. Phys. 9:1977;485-500.
6. Bruzynski S.R. Purified Antineoplaston Fractions and Methods of Treating Neoplastic Disease. 1985;. US patent 4558057; December 10.
7. Sobin L.H., Wittekind C. UICC/TNM Classification of Malignant Tumors. 5th Edition :1997;Wiley-Liss, New York.
8. Abou-Zeid L. Antiestrogen and/or antiprogestin structurally related new drugs of chemotherapeutic value. Ph.D Thesis. (1995);Mansoura University, Egypt.
9. Crombach G. Considerations in rational use of tumor markers in breast carcinoma. Schweiz. Rundsch. Med. Prax. 87:1998;589-594.
10. Lee Y. Carcinoembryonic antigen as a monitor of recurrent breast cancer. J. Surg. Oncol. 20:1982;109-114.
11. Hayes D.F., Zurawski V.R. Jr, Kufe W.D. J. Clin. Oncol. 4:1986;1542-1550.
12. Colomer R., Ruibal A., Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer. 64:1989;1676-1681.
13. Dnistrian A.M., Schwartz M.K., Greeberg E.J., Smith C.A., Schwartz D.C. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin. Chim. Acta. 200:1991;81-94.
14. Safi F., Kohler I., Rottinger E., Beger H. The value of tumor marker CA 15-3 in diagnosing and monitoring breast cancer. Cancer. 68:1991;574-582.
15. Dnistrian A.M., Schwartz M.K., Greenberg E.J., Smith C.A., Schwartz D.C. Evaluation of CA M26 CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol. 12:1991;82-90.
16. Dnistrian A.M., Schwartz M.K., Greenberg E.J., Smith C.A., Dorsa R., Schwartz D.C. CA 549 as a marker in breast cancer. Int. J. Biol. Markers. 6:1991;139-143.
17. Heinze T., Schurenkmper P., Minguillon C., Lichtenegger W. Mammary serum antigen (MSA) CA 549, CA 15-3 and CEA in breast cancer, preoperative sensitivity and correlation to prognostic factors. Anticancer Res. 17:1997;2953-2954.
18. Meisel M., Weise J., Schwesinger G., Straube W. Cancer associated serum antigen (CASA) levels in patients with breast carcinoma and 3 control groups without breast cancer. Arch. Gynecol. Obstet. 1998;159-162.
19. Martoni A., Zamagni C., Bellanova B., Zanichellii L., Vecchi F., Cacciari N., Strocchi E., Pannuti F. CEA, MCA, CA 15-3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur. J. Cancer. 31:1995;1615-1621.
20. Torres M., Pacheco C., Valverde A., Rebollo A.C., Moral A., Vallejo J.A., Mateo A. CA 549 and SP2 in postoperative breast cancer patients Comparison with CA 15-3, CEA and TPA. Int. J. Biol. Markers. 10:1995;94-99.
21. Molina R., Jo J., Filella X., Zanon G., Pahiso J., Munoz M., Farrus B., Latre M.L., Escriche C., Estape J., Ballesta A.M. C-erb B-2 oncoprotein CEA and CA 15-3 in patients with breast cancer: Prognostic value. Breast Cancer Res. Treat. 51:1998;109-119.
22. Nicolini A., Ferrari P., Sagripanti A., Carpi A. The role of tumor markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br. J. Cancer. 79:1999;1443-1447.
23. Tsuda H., Iemura A., Sata M., Uchida M., Yamana K., Hara H. Inhibitory effect of antineoplaston A-10 and AS2-1 on human hepatocellular carcinoma. Kurume Med. J. 43:(2):1996;137-147.
24. Sugita Y., Tsuda H., Maruiwa H., Hirohata M., Shigemori M., Hara H. The effect of antineoplaston, a new antitumor agent on malignant brain tumors. Kurume Med. J. 42:(3):1995;133-140.
25. Tsuda H., Hara H., Eriguchi N., Nishida H., Yashida H., Kumabe T., Sugita Y. Toxicology study on antineoplaston A-10 and AS2-1 in cancer patients. Kurume Med. J. 42:(4):1995;241-249.
26. Tsuda H., Sugihara S., Nishida H., Hara H., Eriguchi N., Ishii K., Sasaki S., Yoshimura S., Tanaka N. The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of hepatocellular carcinoma. Jpn. J. Cancer Res. 83:(5):1992;527-531.
27. Hashimoto K., Koga T., Shintomi Y., Tanaka M., Kakegawa T., Tsuda H., Hara H. The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice. Nippon Gan Chiryo Gakkai Shi. 25:(1):1990;1-5.
28. Tsuda H. Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines. Kurum Med. J. 37:(2):1990;97-104.
29. Hendry L.B., Muldoon T.G., Burzynski S.R., Copland J.A., Lehner A.F. Stereochemical modeling studies of the interaction of antineoplaston A-10 with DNA. Drugs Exp. Clin. Res. 1:1987;77-81.